Laurus Labs is back in focus as the latest research update resets the stock's price target, putting fresh attention on what ...
Laurus Labs Ltd. reported a 174% year-on-year increase in consolidated net profit to ₹252 crore for the third quarter of FY26, while revenue from operations grew 26% to ₹1,778 crore. The company's ...
Net Sales at Rs 1,509.42 crore in December 2025 up 19.3% from Rs. 1,265.19 crore in December 2024. Quarterly Net Profit at Rs ...
Laurus Labs' Q3 net profit soars to ₹252 crore with a 26% revenue increase, driven by strong generics and CDMO demand.
In its investor presentation, Laurus Labs said that they are well on track to deliver healthy operational growth for financial year 2026.
Hosted on MSN
From Laurus Labs To Alkem: SEBI Analysts Spot Bullish Setups In These Five Stocks For Short-Term Trades
Indian equity markets remain in a tight range in the weekly expiry session on Thursday. However, pockets of opportunity are emerging, with SEBI-registered analysts Kavita Agrawal and Vinay Taparia ...
Laurus Labs Ltd (BOM:540222) reports robust financial results with significant growth in its generic division and strategic investments in advanced therapies.
Laurus Labs posted a manifold increase in net profit to ₹252 crore in the third quarter ended December 31, 2025, compared to ₹92 crore in the corresponding quarter of the previous financial year on ...
SUNNYVALE, Calif., May 30, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of ...
Laurus Labs has seen a notable increase in its consensus analyst price target, which has risen from ₹724.14 to ₹815.86. This revision follows renewed analyst optimism, attributed largely to the ...
Hosted on MSN
Laurus Labs share price surges over 18% in June, outperforms Sensex. What's next for this pharma stock?
Laurus Labs share price rose over 2% during Monday's trading session to touch an 52-week high of ₹720.90 apiece on the BSE, marking the stock's third consecutive day of gains in a bullish trend. So ...
The strategic alliance includes an initial seven high-value advanced intermediates and active pharmaceutical ingredients, including Willow's corticosteroid programs The agreement with Laurus is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results